ditto @ditto4885
Joined February 2024-
Tweets1
-
Followers2
-
Following20
-
Likes10
Skylar Kielbasa @KielbaSkyl
0 Followers 73 Following
ASCO @ASCO
147K Followers 2K Following Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.
ESMO - Eur. Oncology @myESMO
75K Followers 873 Following The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Stephen V Liu, MD @StephenVLiu
24K Followers 3K Following Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
J&J Innovative Medici.. @JNJInnovMed
16K Followers 801 Following We innovate with purpose to lead where medicine is going. Channel run by Janssen Global Services LLC, NJ, USA. Our guidelines: https://t.co/aMAhBk9BBJ
Bloomberg @Bloomberg
732K Followers 51 Following Connecting decision makers to a dynamic network of information, people and ideas.
Real Time Economics @WSJecon
967K Followers 94 Following Economic insight from The Wall Street Journal. Want more? Sign up for our daily Real Time Economics newsletter: https://t.co/HX7UM0pmuK
MarketWatch @MarketWatch
4.6M Followers 231 Following News, personal finance & commentary from MarketWatch. For customer support, visit https://t.co/Uu49STq7M6
WSJ Markets @WSJmarkets
900K Followers 534 Following Breaking news, smart analysis and in-depth features on global markets and finance from The Wall Street Journal.
Reuters Business @ReutersBiz
2.7M Followers 247 Following The latest business and financial news from around the 🌍 with insights from @breakingviews. Our new daily podcast is here: https://t.co/WoRUGLyyeH
Bloomberg Markets @markets
1.7M Followers 230 Following Breaking news and analysis on global financial markets Sign up for newsletters: https://t.co/3zp754sbuD Catch up on Markets Wrap: https://t.co/PF0mrEttGc
Bloomberg Economics @economics
605K Followers 2K Following Breaking economics news and analysis from @business, the first word in global business and finance. Sign up for our daily newsletter: https://t.co/0m3cdbZZdY
Reuters Breakingviews @Breakingviews
131K Followers 4K Following The world's leading source of agenda-setting financial insight and commentary. Sign up for a free trial of our professional service at https://t.co/wQHuIdv5Fb
Investing.com @Investingcom
1.1M Followers 290 Following 📈 Real-time global financial market data, news, analysis, charts, tools & more • In 30 languages via our app or website • FREE, for everyone, anywhere! 🌎
Yahoo Finance @YahooFinance
1.8M Followers 311 Following The world’s biggest business news platform: https://t.co/EhQ75nXob3 Get the free Yahoo Finance app & subscribe to our morning newsletter, the Morning Brief ⬇️
CNBC Now @CNBCnow
782K Followers 54 Following Breaking news, real-time market updates & more from @CNBC.
Bloomberg @business
9.5M Followers 80 Following The first word in business news. Newsletters: https://t.co/nWaCxHSKuU Podcasts: https://t.co/096e9xMbPz
The Wall Street Journ.. @WSJ
20.6M Followers 1K Following Sign up for our newsletters and alerts: https://t.co/QevH0DLisA | Got a tip? https://t.co/iXIigdOLPr | For WSJ customer support: https://t.co/DZgH9n4vAI
Financial Times @FT
5.9M Followers 1K Following Big stories and breaking news headlines as they are published on https://t.co/EYmAcRLBHv. Register here to access free articles: https://t.co/NRg2hritkA
Elon Musk @elonmusk
182.0M Followers 588 Following
The MARIPOSA trial of amivantamab + lazertinib vs standard-of-care osimertinib for the treatment of EGFR-mutated #NSCLC had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. @AlexSpiraMDPhD @VCSpecialists targetedonc.com/view/amivantam…
Dr. @charocampelo at #ELCC24 discusses the MARIPOSA study (1L amivantamab + lazertinib vs osimertinib) and we see that about half of pts required dose interruptions in first 4m but that did not compromise PFS benefit. Toxicity was early, decreased over time. #ESMOAmbassadors
My team at @JNJInnovMed is sharing data at #ELCC24, reinforcing the potential of our innovative targeted therapy. These latest findings demonstrate our commitment to advancing the science of #LungCancer through our robust clinical program: bit.ly/3wZVfzK
Looking forward to amivantamab updates at #ELCC24 1️⃣ Ph 3 MARIPOSA: 1L Ami + lazertinib, impact of dose interruptions (#1001) 2️⃣ Ph 1 PALOMA: Infusion-related reactions w/ subcutaneous Ami (#839) 3️⃣ Ph 3 PAPILLON: 1L Ami + chemo, post-progression analyses (#844) 4️⃣ Ph 3…
My team at @JNJInnovMed is sharing data at #ELCC24, reinforcing the potential of our innovative targeted therapy. These latest findings demonstrate our commitment to advancing the science of #LungCancer through our robust clinical program: bit.ly/3wZVfzK
ELCC 2024 spots: great talk going through the landscape of possible treatment options to overcome Osimertinib resistance in advanced NSCLC. Among these Avimantamab + Lazertinib combo is probably practice changing. ADCs show activity but phase III trial are needed
At #JNJOncology, we’re dedicated to transforming the treatment of #LungCancer. Our latest data demonstrate the impact of our science and reinforce our commitment to redefining the standard of care. Learn more at #ELCC24: bit.ly/3wZVfzK
Updated results from first-line lazertinib for EGFR NSCLC in LASER201 study . 1L lazertinib 240mg po daily had RR 70%, DCR 86%, mDOR 23.5m, mPFS 24.6m, mOS not reached, OS rate at 54m was 55%. Rash in 54%, diarrhea 47% (7% G3).
@elonmusk Did you take this video on a Nokia phone ? The video quality is similar to when we photograph UFO’s
@elonmusk Oh cool, the same camera they use to get UFO footage
UPDATE: US FDA Priority Review received for Phase 3 MARIPOSA submission bit.ly/3uQSZdf
Building on a succession of milestones within our #LungCancer portfolio, our latest U.S. FDA submission represents our third in EGFR-mutated non-small cell lung cancer (NSCLC) in 4 months. Learn more here: bit.ly/3RQEpeq
Trends for United States
You might like
